FDA lifts a hold on Flexion pain drug

Burlington, MA-based Flexion ($FLXN) says that the FDA has lifted its clinical hold on its lead pain drug candidate, FX006. The biotech reports that had completed the FDA's "requested testing and investigation related to what was originally reported as a single case of septic arthritis of the knee." The removal of the regulatory obstacle clears the way for investigators to resume a Phase IIb study and launch Phase III in early 2015. Flexion shares were up about 6% this morning. Release

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.